Epirubicin, cisplatin plus 5-fluorouracil (ECF) versus docetaxel, cisplatin with 5-fluorouracil (DCF) therapy as a regimen for locally further inoperable or metastatic esophageal and gastric cancer

Chengwei Zhang

doi:10.54254/2753-8818/2024.19871

Article Information

Received: 28 December 2024

Published: 10 January 2025

DOI: https://doi.org/10.54254/2753-8818/2024.19871

Article Type: Research Article

Cite this article

Zhang,C. (2025). Epirubicin, cisplatin plus 5-fluorouracil (ECF) versus docetaxel, cisplatin with 5-fluorouracil (DCF) therapy as a regimen for locally further inoperable or metastatic esophageal and gastric cancer. Theoretical and Natural Science,78,38-46.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.78

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Sio-Hou Wong, Endoscopic submucosal dissection for early esophageal squamous cell carcinoma after ligation and sclerotherapy of esophageal and gastric varices, Elsevier Masson SAS, 2024. DOI: 10.1016/j.dld.2024.01.001

[2]Oyama T. Esophageal ESD: Technique and Prevention of Complications. Gastrointest Endosc Clin N Am. 2014;24(2):201–12.

[3]Ahmed Y, Othman M. EMR/ESD: Techniques, Complications, and Evidence. Curr Gastroenterol Rep. 2020;22(8):39.

[4]Mouridsen HT, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksborg S, et al. (January 1990). Current status of epirubicin (Farmorubicin) in the treatment of solid tumors. Acta Oncologica. 29(3):257–285.

[5]Taymaz-Nikerel H, Karabekmez ME, Eraslan S, et al. Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Rep. 2018;8:13672.

[6]The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.

[7]Airley R. Cancer Chemotherapy: Basic Science to the Clinic. John Wiley & Sons; 2009. p. 76. ISBN: 9780470092569. Archived from the original on 5 November 2017.

[8]Brown A. Cisplatin-Based Chemotherapy of Human Cancers. J Cancer Sci Ther. 2019;11(4):97. Epub 2019 Apr 8.

[9]Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587(2-3):194-205. DOI: 10.1016/s0925-4439(02)00082-0. PMID: 12084461.

[10]Montero A. Docetaxel for Treatment of Solid Tumors: A Systematic Review of Clinical Data. Oncol Lancet. 2005;6(4):229-239.

[11]Tyson AM, Gay WE. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. Ann Pharmacother. 2010;44:922-5.

[12]Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;6:3680-6.

[13]Muthuramalingam S, Gale J, Bradbury J. Dexrazoxane efficacy for anthracycline extravasation: Use in UK clinical practice. Int J Clin Pract. 2013;67:244-9.

[14]Arroyo PA, Perez RU, Feijoo MA, Hernandez MA. Good clinical and cost outcomes using dexrazoxane to treat accidental Epirubicin extravasation. J Cancer Res Ther. 2010;6:573-4.

[15]Andrea Giampreti, Maria Lucà, Mariapina Gallo, et al. Dexrazoxane for rapid extended livedo reticularis-like skin reaction due to systemic epirubicin diffusion during transcatheter arterial chemoembolization procedure for hepatocellular carcinoma. J Cancer Res Ther. 2021;22-Nov-2021.